sr141716 has been researched along with cholecystokinin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amico, MC; Morrone, LA; Palmery, M; Romanelli, L; Tucci, P; Valeri, P | 1 |
| Alemany, M; Cabot, C; Fernández-López, JA; Ferrer-Lorente, R | 1 |
| Al-Zaman, Y; Aylwin, S | 1 |
| Inno, J; Kurrikoff, K; Matsui, T; Vasar, E | 1 |
| Bowser, ME; Chhatwal, JP; Davis, M; Gutman, AR; Maguschak, KA; Ressler, KJ; Yang, Y | 1 |
| Bowers, ME; Ressler, KJ | 1 |
1 review(s) available for sr141716 and cholecystokinin
| Article | Year |
|---|---|
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
5 other study(ies) available for sr141716 and cholecystokinin
| Article | Year |
|---|---|
Involvement of the cannabinoid CB1 receptor in the opioid inhibition of the response to cholecystokinin and acute withdrawal response.
Topics: Acute Disease; Adenosine A1 Receptor Antagonists; Analgesics, Opioid; Animals; Benzoxazines; Cholecystokinin; Dose-Response Relationship, Drug; Guinea Pigs; Ileum; In Vitro Techniques; Male; Morpholines; Muscle Contraction; Muscle, Smooth; Naloxone; Naphthalenes; Narcotic Antagonists; Neurons; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Opioid, kappa; Receptors, Opioid, mu; Rimonabant; Substance Withdrawal Syndrome; Theophylline | 2005 |
Effects of combined oleoyl-estrone and rimonabant on overweight rats.
Topics: Animals; Anti-Obesity Agents; Appetite; Blood Glucose; Cholecystokinin; Cholesterol; Drug Synergism; Drug Therapy, Combination; Eating; Energy Metabolism; Estrone; Fatty Acids, Nonesterified; Ghrelin; Glucagon-Like Peptide 1; Insulin; Leptin; Male; Obesity; Oleic Acids; Overweight; Peptide Hormones; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Triglycerides | 2007 |
Stress-induced analgesia in mice: evidence for interaction between endocannabinoids and cholecystokinin.
Topics: Analgesia; Animals; Brain; Cannabinoid Receptor Modulators; Cholecystokinin; Endocannabinoids; Gene Expression; Gene Expression Regulation; Mice; Mice, Mutant Strains; Naloxone; Narcotic Antagonists; Pain Threshold; Piperidines; Pyrazoles; Receptor, Cholecystokinin B; Receptors, Cannabinoid; Receptors, Opioid; Rimonabant; Spinal Cord; Stress, Psychological | 2008 |
Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning.
Topics: Amygdala; Animals; Benzodiazepines; Cannabinoid Receptor Modulators; Cholecystokinin; Conditioning, Psychological; Corpus Striatum; Endocannabinoids; Extinction, Psychological; Fear; Learning; Male; Pentagastrin; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cholecystokinin B; Reflex, Startle; Rimonabant; RNA, Messenger | 2009 |
Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention.
Topics: Amidohydrolases; Animals; Benzamides; Cannabinoid Receptor Antagonists; Carbamates; Cholecystokinin; Conditioning, Psychological; Cues; Dose-Response Relationship, Drug; Extinction, Psychological; Fear; Male; Mice; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cholecystokinin B; Rimonabant | 2015 |